The approach described in this study of targeted downregulation of KLF2 in activated CD8+ T cells using a systemically administered drug formulation, the 4-1BB antibody conjugated KLF2 siRNA, will reach activated CD8+ T cells throughout the body and hence improve immune control of tumor lesions wherever they may be. Here, KLF2 is linked to neoplasm.